Promising Trial Data and Strategic Focus Drive Buy Rating for Kura Oncology

Charles Zhu, an analyst from LifeSci Capital, maintained the Buy rating on Kura Oncology (KURA – Research Report). The associated price target remains the same with $24.00.

Charles Zhu’s rating is based on the promising data from Kura Oncology’s KOMET-001 trial, which evaluated ziftomenib as a monotherapy for patients with relapsed/refractory NPM1-mutated acute myeloid leukemia (AML). The trial results showed response rates that are consistent with previous data and comparable to competitors, indicating a potential market opportunity for Kura Oncology. The company has submitted new drug applications for their menin inhibitors, which could lead to the first potential FDA approval for ziftomenib, driving significant revenue.
Additionally, ziftomenib demonstrated a favorable safety profile with fewer severe treatment-related cytopenias compared to its competitor, revumenib. Despite a slightly lower duration of response, the overall safety and efficacy data support the potential of ziftomenib in the treatment landscape for AML. These factors, combined with the company’s strategic focus on combination therapies, underpin Charles Zhu’s Buy rating for Kura Oncology.

In another report released today, Barclays also maintained a Buy rating on the stock with a $11.00 price target.